Comparison of Immune Response Assessment in Colon Cancer by Immunoscore (Automated Digital Pathology) and Pathologist Visual Scoring
暂无分享,去创建一个
J. Galon | F. Hermitte | A. Kassambara | A. Catteau | A. Lui | I. Boquet | F. Arnoux | Alicia K. Tanner | Yoann Lovera | Marie Latil
[1] E. Oki,et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] F. Marincola,et al. Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] R. Labianca,et al. Localised Colon Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] Yong Zhou,et al. The prognostic value of Immunoscore in patients with cancer: A pooled analysis of 10,328 patients , 2020, The International journal of biological markers.
[5] J. Galon,et al. Analytical validation of the Immunoscore and its associated prognostic value in patients with colon cancer , 2020, Journal for immunotherapy of cancer.
[6] P. Laurent-Puig,et al. Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] A. Benson,et al. Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer , 2020, JNCI cancer spectrum.
[8] P. Gibbs,et al. Tumour infiltrating lymphocyte status is superior to histological grade, DNA mismatch repair and BRAF mutation for prognosis of colorectal adenocarcinomas with mucinous differentiation , 2020, Modern Pathology.
[9] P. Laurent-Puig,et al. The consensus Immunoscore in phase 3 clinical trials; potential impact on patient management decisions , 2020, Oncoimmunology.
[10] J. Galon,et al. Usefulness and robustness of Immunoscore for personalized management of cancer patients , 2020, Oncoimmunology.
[11] Ahmedin Jemal,et al. Cancer treatment and survivorship statistics, 2019 , 2019, CA: a cancer journal for clinicians.
[12] J. Barrett,et al. The Immunoscore: Colon Cancer and Beyond , 2019, Clinical Cancer Research.
[13] F. Marincola,et al. Immunoscore clinical utility to identify good prognostic colon cancer stage II patients with high-risk clinico-pathological features for whom adjuvant treatment may be avoided. , 2019, Journal of Clinical Oncology.
[14] F. Marincola,et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study , 2018, The Lancet.
[15] R. Jorissen,et al. Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes , 2018, Gut.
[16] P. Laurent-Puig,et al. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. , 2017, European journal of cancer.
[17] G. Wang,et al. Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis , 2014, British Journal of Cancer.
[18] F. Marincola,et al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours , 2013, The Journal of pathology.
[19] F. Marincola,et al. Cancer classification using the Immunoscore: a worldwide task force , 2012, Journal of Translational Medicine.
[20] M. McHugh. Interrater reliability: the kappa statistic , 2012, Biochemia medica.
[21] D. McMillan,et al. The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer. , 2012, Cancer treatment reviews.
[22] C. Sautès-Fridman,et al. The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.
[23] J. Galon,et al. The prognostic impact of anti-cancer immune response: a novel classification of cancer patients , 2011, Seminars in Immunopathology.
[24] S. Yun,et al. Clinical impact of tumor‐infiltrating lymphocytes for survival in stage II colon cancer , 2010, Cancer.
[25] L. Sobin,et al. Digestive System Tumours , 2010 .
[26] Zlatko Trajanoski,et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] J. Galon,et al. The essential role of the in situ immune reaction in human colorectal cancer , 2008, Journal of leukocyte biology.
[28] Z. Trajanoski,et al. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.
[29] D. McMillan,et al. The clinical utility of the local inflammatory response in colorectal cancer. , 2014, European journal of cancer.